Triazole antifungal drug interactions—practical considerations for excellent prescribing
Journal of Antimicrobial Chemotherapy · 03.06.2024 · 79 (6) · 1203-1217
DOI: 10.1093/jac/dkae103 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 17.04.2024. Verfasst von Russell Lewis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Drug Interactions, Antifungal Agents, Triazoles. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Royal College of Pathologists.
Abstract (Originalsprache)
Systemic antifungal therapy is critical for reducing the mortality from many invasive and chronic fungal infections. Triazole antifungals are the most frequently prescribed antifungals but require attention to dosing and drug interactions. Nearly 600 severe drug–drug interactions and over 1100 moderate interactions requiring dose modifications are described or anticipated with systemic antifungal agents (see https://www.aspergillus.org.uk/antifungal-drug-interactions/). In this article, we address the common and less common, but serious, drug interactions observed in clinical practice with triazole antifungals, including a group of drugs that cannot be prescribed with all or most triazole antifungals (ivabradine, ranolazine, eplerenone, fentanyl, apomorphine, quetiapine, bedaquiline, rifampicin, rifabutin, sirolimus, phenytoin and carbamazepine). We highlight interactions with drugs used in children and new agents introduced for the treatment of haematological malignancies or graft versus host disease (midostaurin, ibrutinib, ruxolitinib and venetoclax). We also summarize the multiple interactions between oral and inhaled corticosteroids and triazole antifungals, and the strategies needed to optimize the therapeutic benefits of triazole antifungal therapy while minimizing potential harm to patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, University of Padua, Padua, Italy.
- Antifungal Database Consultancy Pharmacist, Fungal Infection Trust, PO Box 482, Macclesfield, Cheshire SK10 9AR, UK.
- Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
- Division of Infectious Diseases, Department of Internal Medicine and Center for Infectious Diseases Research, American University of Beirut Medical Center, Beirut, Lebanon.
- Department of Microbiology, Immunology, and Transplantation, Department of Haematology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
- Department of Health Sciences, Infectious Diseases Clinic, University of Genoa and Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
ORCID-Profile: Russell Lewis, Saarah Niazi-Ali, Andreas H Groll
Förderung
- Royal College of Pathologists
Zitieren
APA
Lewis, R., Niazi-Ali, S., McIvor, A., Kanj, S. S., Maertens, J., Bassetti, M., Levine, D., Groll, A. H., & Denning, D. W. (2024). Triazole antifungal drug interactions—practical considerations for excellent prescribing. Journal of Antimicrobial Chemotherapy, 79(6), 1203-1217. https://doi.org/10.1093/jac/dkae103
Vancouver
Lewis R, Niazi-Ali S, McIvor A, Kanj SS, Maertens J, Bassetti M, et al. Triazole antifungal drug interactions—practical considerations for excellent prescribing. Journal of Antimicrobial Chemotherapy. 2024;79(6):1203-1217. doi:10.1093/jac/dkae103
BibTeX
@article{Lewis2024,
author = {Lewis, Russell and Niazi-Ali, Saarah and McIvor, Andrew and Kanj, Souha S and Maertens, Johan and Bassetti, Matteo and Levine, Deborah and Groll, Andreas H and Denning, David W},
title = {Triazole antifungal drug interactions—practical considerations for excellent prescribing},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {6},
pages = {1203--1217},
doi = {10.1093/jac/dkae103}
}
EUVIMED